Review article: Why, when and how to de-escalate therapy in inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 4, 2014, Pages 338-353

  Pariente, B ^a   Laharie, D ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DRUG ANTIBODY; IMMUNOSTIMULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NARCOTIC ANALGESIC AGENT; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

ANOPERINEAL FISTULA; ANUS FISTULA; CLINICAL TRIAL (TOPIC); CONGENITAL MALFORMATION; CROHN DISEASE; DISEASE ACTIVITY; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FETUS WASTAGE; GROWTH RETARDATION; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; IMMUNOGENICITY; INFECTION; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MONONUCLEOSIS; MONOTHERAPY; NEOPLASM; NON MELANOMA SKIN CANCER; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; POSTMONONUCLEOSIS LYMPHOPROLIFERATION; POSTTRANSPLANT LIKE LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; T CELL LYMPHOMA; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PATIENT SELECTION; PREGNANCY; RECURRENCE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84904425206     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12838     Document Type: Review

References (81)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel J-F, Sandborn WJ,. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-97.
2. Pariente B, Cosnes J, Danese S, et al,. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011; 17: 1415-22.
3. Ordás I, Feagan BG, Sandborn WJ,. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut 2011; 60: 1754-63.
4. Sandborn WJ, Hanauer S, Van Assche G, et al,. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014; doi: 10.1016/j.crohns.2014.02.021 [Epub ahead of print].
5. Baert F, Moortgat L, Van Assche G, et al,. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8.
6. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
7. Panaccione R, Ghosh S, Middleton S, et al,. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400.
8. Feagan BG, McDonald JWD, Panaccione R, et al,. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014; 146: 681-8.
9. Sokol H, Seksik P, Carrat F, et al,. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-8.
10. Kestens C, van Oijen MGH, Mulder CLJ, et al,. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents. Clin Gastroenterol Hepatol 2013; 11: 826-31.
11. Bouguen G, Siproudhis L, Gizard E, et al,. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol 2013; 11: 975-81.
12. Jones J, Kaplan GG, Peyrin-Biroulet L, et al,. Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: a Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data. Gastro-enterology 2013; 144 (Suppl. 1): S-179.
13. Reenaers C, Louis E, Belaiche J, Seidel L, Keshav S, Travis S,. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment Pharmacol Ther 2012; 36: 1040-8.
14. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P,. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
15. Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ,. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007; 133: 1779-86.
16. TM registry. Am J Gastroenterol 2012; 107: 1409-22.
17. Toruner M, Loftus EV Jr, Harmsen WS, et al,. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36.
18. Lin Z, Bai Y, Zheng P,. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol 2011; 23: 1100-10.
19. Fidder H, Schnitzler F, Ferrante M, et al,. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
20. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ,. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009; 104: 2524-33.
21. Cottone M, Kohn A, Daperno M, et al,. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 30-5.
22. Westhovens R, Yocum D, Han J, et al,. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 1075-86.
23. Targan SR, Hanauer SB, van Deventer SJ, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
24. Present DH, Rutgeerts P, Targan S, et al,. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
25. Biancone L, Petruzziello C, Orlando A, et al,. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis 2011; 17: 758-66.
26. ™ Registry. Am J Gastroenterol 2014; 109: 212-23.
27. Mariette X, Matucci-Cerinic M, Pavelka K, et al,. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-904.
28. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD,. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143: 390-9.
29. Beaugerie L, Brousse N, Bouvier AM, et al,. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
30. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al,. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-8.
31. Magro F, Peyrin-Biroulet L, Sokol H, et al,. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 2014; 8: 31-44.
32. Kotlyar DS, Osterman MT, Diamond RH, et al,. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41.
33. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED,. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013; 108: 99-105.
34. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS,. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 15-22.
35. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM,. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88: 589-92.
36. Beghin D, Cournot M-P, Vauzelle C, Elefant E,. Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol 2011; 38: 628-32.
37. Coelho J, Beaugerie L, Colombel JF, et al,. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60: 198-203.
38. Mahadevan U, Wolf DC, Dubinsky M, et al,. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-92.
39. Schnitzler F, Fidder H, Ferrante M, et al,. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17: 1846-54.
40. Zelinkova Z, van der Ent C, Bruin KF, et al,. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11: 318-21.
41. Mahadevan U, Kane S, Sandborn WJ, et al,. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005; 21: 733-8.
42. Lichtenstein GR, Feagan BG, Cohen RD, et al,. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
43. Bortlik M, Machkova N, Duricova D, et al,. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scand J Gastroenterol 2013; 48: 951-8.
44. Chaparro M, Gisbert JP,. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol 2011; 12: 765-73.
45. Dretzke J, Edlin R, Round J, et al,. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess 2011; 15: 1-244.
46. Choi GKH, Collins SDE, Greer DP, et al,. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. J Crohns Colitis 2014; 8: 375-83.
47. Dignass A, Van Assche G, Lindsay JO, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
48. Krieckaert CL, Nurmohamed MT, Wolbink GJ,. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012; 71: 1914-5.
49. Moreau AC, Paul S, Del Tedesco E, et al,. Association Between 6-Thioguanine Nucleotides Levels and Clinical Remission in Inflammatory Disease: a Meta-analysis. Inflamm Bowel Dis 2014; 20: 464-71.
50. Roblin X, Oussalah A, Chevaux J-B, Sparrow M, Peyrin-Biroulet L,. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis 2011; 17: 2480-7.
51. Van den Bemt BJF, den Broeder AA, Snijders GF, et al,. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 2008; 67: 1697-701.
52. Vande Casteele N, Compernolle G, Ballet V, et al,. Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Crohns Colitis 2012; 6 (Suppl.): S6.
53. Baert F, Glorieus E, Reenaers C, et al,. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis 2013; 7: 154-60.
54. Rahier JF, Ben-Horin S, Chowers Y, et al,. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
55. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al,. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8.
56. Oussalah A, Chevaux J-B, Fay R, Sandborn WJ, Bigard M-A, Peyrin-Biroulet L,. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010; 105: 1142-9.
57. Ben-Horin S, Waterman M, Kopylov U, et al,. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444-7.
58. Saleem B, Keen H, Goeb V, et al,. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010; 69: 1636-42.
59. Van den Broek M, Klarenbeek NB, Dirven L, et al,. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011; 70: 1389-94.
60. Lémann M, Mary J-Y, Duclos B, et al,. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
61. Costes L, Colombel JF, Mary JY, et al,. Long Term Follow-Up of a Cohort of Steroid-Dependent Crohn's Disease Patients Included in a Randomized Trial Evaluating Short Term Infliximab Combined with Azathioprine. Gastroenterology 2008; 134 (Suppl. 1): A-134.
62. Louis E, Mary J-Y, Vernier-Massouille G, et al,. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
63. Waugh AWG, Garg S, Matic K, et al,. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010; 32: 1129-34.
64. Steenholdt C, Molazahi A,. Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012; 47: 518-27.
65. Molnár T, Lakatos PL, Farkas K, et al,. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013; 37: 225-33.
66. Lim W-C, Hanauer S,. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev 2010; 12: CD008870.
67. Loftus EV Jr, Kane SV, Bjorkman D,. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 179-89.
68. Dignass A, Lindsay JO, Sturm A, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030.
69. Kane SV, Cohen RD, Aikens JE, Hanauer SB,. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33.
70. Kane SV, Accortt NA, Magowan S, Brixner D,. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther 2009; 29: 855-62.
71. Higgins PDR, Rubin DT, Kaulback K, Schoenfield PS, Kane SV,. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009; 29: 247-57.
72. Velayos FS, Terdiman JP, Walsh JM,. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-53.
73. Hawthorne AB, Logan RF, Hawkey CJ, et al,. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-2.
74. Cassinotti A, Actis GC, Duca P, et al,. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009; 104: 2760-7.
75. Lémann M, Mary J-Y, Colombel J-F, et al,. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-8.
76. Treton X, Bouhnik Y, Mary J-Y, et al,. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-5.
77. French H,. Mark Dalzell A, Srinivasan R, El-Matary W. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis. Dig Dis Sci 2011; 56: 1929-36.
78. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
79. Colombel J-F, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
80. Roumeguère P, Bouchard D, Pigot F, et al,. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: results from a prospective study. Inflamm Bowel Dis 2011; 17: 69-76.
81. Ng SC, Plamondon S, Gupta A, et al,. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol 2009; 104: 2973-86.